NASDAQ:CSTL Castle Biosciences (CSTL) Stock Price, News & Analysis $21.51 +0.25 (+1.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$21.54 +0.04 (+0.16%) As of 04/17/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Castle Biosciences Stock (NASDAQ:CSTL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Castle Biosciences alerts:Sign Up Key Stats Today's Range$21.13▼$21.8150-Day Range$18.57▼$27.8552-Week Range$16.97▼$35.84Volume454,033 shsAverage Volume382,391 shsMarket Capitalization$620.46 millionP/E Ratio107.56Dividend YieldN/APrice Target$38.75Consensus RatingBuy Company OverviewCastle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Read More… Castle Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCSTL MarketRank™: Castle Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 477th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCastle Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Castle Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Castle Biosciences are expected to decrease in the coming year, from $0.44 to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is 107.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is 107.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.86.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Castle Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.43% of the float of Castle Biosciences has been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 5.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.43% of the float of Castle Biosciences has been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 5.11%, indicating that investor sentiment is improving significantly. News and Social Media4.0 / 5News Sentiment1.19 News SentimentCastle Biosciences has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Castle Biosciences this week, compared to 4 articles on an average week.Search Interest3 people have searched for CSTL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $748,045.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Castle Biosciences' insider trading history. Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Stock News HeadlinesInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,236 Shares of StockMarch 29, 2025 | insidertrades.comCastle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A ConcernApril 14, 2025 | seekingalpha.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.April 19, 2025 | Altimetry (Ad)Brokerages Set Castle Biosciences, Inc. (NASDAQ:CSTL) Target Price at $38.75April 10, 2025 | americanbankingnews.comCastle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative PartnershipsApril 8, 2025 | globenewswire.comCastle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive YearApril 7, 2025 | globenewswire.comCastle Biosciences announces publication of papers on DecisionDx-Melanoma testApril 4, 2025 | markets.businessinsider.comPublication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma TestApril 3, 2025 | globenewswire.comSee More Headlines CSTL Stock Analysis - Frequently Asked Questions How have CSTL shares performed this year? Castle Biosciences' stock was trading at $26.65 on January 1st, 2025. Since then, CSTL stock has decreased by 19.3% and is now trading at $21.51. View the best growth stocks for 2025 here. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings data on Monday, November, 4th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.14. The firm had revenue of $85.78 million for the quarter, compared to analysts' expectations of $78.55 million. Castle Biosciences had a net margin of 1.95% and a trailing twelve-month return on equity of 1.47%. Read the conference call transcript. When did Castle Biosciences IPO? Castle Biosciences (CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Castle Biosciences' major shareholders? Top institutional investors of Castle Biosciences include Tritonpoint Wealth LLC (0.14%), Rhumbline Advisers (0.14%), Summit Global Investments (0.11%) and Harbor Capital Advisors Inc. (0.06%). Insiders that own company stock include Kristen M Oelschlager, Derek J Maetzold, Tobin W Juvenal, Frank Stokes, Ellen Goldberg, Tiffany Olson and Daniel Bradbury. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Castle Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), PayPal (PYPL), Adobe (ADBE), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings11/04/2024Today4/18/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:CSTL CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees540Year FoundedN/APrice Target and Rating Average Stock Price Target$38.75 High Stock Price Target$44.00 Low Stock Price Target$30.00 Potential Upside/Downside+80.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.62 Trailing P/E Ratio107.56 Forward P/E Ratio48.89 P/E GrowthN/ANet Income$-57,470,000.00 Net Margins1.95% Pretax Margin3.57% Return on Equity1.47% Return on Assets1.27% Debt Debt-to-Equity Ratio0.02 Current Ratio7.78 Quick Ratio7.64 Sales & Book Value Annual Sales$332.07 million Price / Sales1.87 Cash FlowN/A Price / Cash FlowN/A Book Value$14.54 per share Price / Book1.48Miscellaneous Outstanding Shares28,839,000Free Float25,990,000Market Cap$620.33 million OptionableOptionable Beta1.11 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CSTL) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.